The Health Sciences Authority (HSA) Singapore has announced a critical update regarding the revision of the regulatory fee for health products, which was published on the HSA website in November 2021.
The regulation of health products is managed by HSA for the maintenance of the required standards of quality, safety, and efficacy, and these activities require funds for successful execution and completion. There will be an implementation of a fee increase (averaging 3%), with a minimum increase of $1 and capped at $200 per fee item, which will be in effect from 1 July 2022.
The revision of these fees is important as reclaim of some costs incurred by HSA is required, as there are costs for the services rendered to businesses. These funds directly help HSA and will cover the cost of registration, licensing, notification and permit issuance for therapeutic products, medical devices, Chinese proprietary medicines, cosmetic products, oral dental gums, and retail pharmacies.
The products and services directly impacted by this revision are medical devices, therapeutic products, medicinal products, active pharmaceutical ingredients, controlled drugs and psychotropic substances, Chinese proprietary medicines, cosmetic products, retail pharmacy licence, and medical advertisements & sales promotion.
More details can be found in “Regulatory fee revision for health products, November 2021”: https://www.hsa.gov.sg/announcements/regulatory-updates/fee-revision2022